



**HAL**  
open science

## **Soluble CD14 acts as a DAMP in human macrophages: origin and involvement in inflammatory cytokine/chemokine production**

Manuella Leveque, Karin Simonin-Le Jeune, Stéphane Jouneau, Solenn Moulis, Benoit Desrues, Chantal Belleguic, Graziella Brinchault, Sophie Le Trionnaire, Jean-Pierre Gangneux, Marie-Thérèse Dimanche-Boitrel, et al.

### ► **To cite this version:**

Manuella Leveque, Karin Simonin-Le Jeune, Stéphane Jouneau, Solenn Moulis, Benoit Desrues, et al.. Soluble CD14 acts as a DAMP in human macrophages: origin and involvement in inflammatory cytokine/chemokine production. *FASEB Journal*, 2017, 31 (5), pp.1891-1902. 10.1096/fj.201600772R . hal-01526434

**HAL Id: hal-01526434**

**<https://univ-rennes.hal.science/hal-01526434v1>**

Submitted on 12 Jul 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1           **Soluble CD14 acts as a DAMP in human macrophages: origin and involvement in**  
2                           **inflammatory cytokine/chemokine production**

3  
4           Manuella Lévêque<sup>\*, ‡</sup>, Karin Simonin-Le Jeune<sup>\*, ‡</sup>, Stéphane Jouneau<sup>†, ‡, §</sup>, Solenn Moulis<sup>\*, ‡</sup>,  
5           Benoit Desrues<sup>§, ‡, φ</sup>, Chantal Belleguic<sup>§</sup>, Graziella Brinchault<sup>§</sup>, Sophie Le Trionnaire<sup>\*, ‡</sup>, Jean-  
6           Pierre Gangneux<sup>‡, §</sup> Marie-Thérèse Dimanche-Boitrel<sup>\*, ‡</sup> and Corinne Martin-Chouly<sup>\*, ‡, 1</sup>

7           \*Research Institute for Environnemental and Occupationnal Health (IRSET) INSERM U1085,  
8           team ‘Stress Membrane and Signaling,’ F-35043 Rennes, France.

9           †Research Institute for Environnemental and Occupationnal Health (IRSET) INSERM U1085,  
10           team ‘Chemical contaminant immunity and inflammation,’ F-35043 Rennes, France.

11           ‡University of Rennes 1, UMS Biosit, F-35000 Rennes, France.

12           §Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la  
13           Mucoviscidose, F-35064 Rennes, France

14           φURL440-COSS, Centre Eugène Marquis, F-35064 Rennes, France

15  
16           **<sup>1</sup>Corresponding author:**

17           Dr. Corinne Martin-Chouly

18           2, avenue du Pr Léon Bernard

19           35043 RENNES Cedex FRANCE

20           E-mail: corinne.chouly@univ-rennes1.fr

21           Tel: (+33) 223234904

22           Fax: (+33) 223235055

23  
24           **Short title:** sCD14 in human macrophages

29 **ABBREVIATIONS**

30

31 Abbreviations used in this article: sCD14, soluble form of CD14; CF, cystic fibrosis; DAMPs,  
32 danger-associated molecular patterns; ER, Endoplasmic Reticulum; FEV1, Force Expiratory  
33 Volume in one second; NLRs, NOD-like receptors; PAMPs, pathogen-associated molecular  
34 patterns; PI-PLC, phosphatidylinositol-phospholipase C.

35

36 **ABSTRACT**

37  
38 The innate immune system is able to detect bacterial lipopolysaccharide (LPS) through the pattern  
39 recognition receptor CD14, which delivers LPS to various TLR signaling complexes that  
40 subsequently induce intracellular pro-inflammatory signaling cascades. In a previous study, we  
41 showed the overproduction of the soluble form of CD14 (sCD14) by macrophages from patients  
42 with cystic fibrosis (CF). CF is an autosomal recessive disorder that is caused by mutations in the  
43 gene that encodes the CFTR protein and characterized by persistent inflammation. Macrophages  
44 play a significant role in the initial stages of this disease due to their inability to act as suppressor  
45 cells leading to chronic inflammation in CF. In this work, we investigated the origin of sCD14 by  
46 human macrophages and studied the effect of sCD14 on the production of inflammatory  
47 cytokine/chemokine. Our data indicate that sCD14 stimulate pro-inflammatory  
48 cytokine/chemokine production in a manner that is independent of LPS but dependent on the  
49 TLR-4/CD14 membrane complex, NF- $\kappa$ B and the inflammasome. Therefore sCD14,  
50 overproduced by CF macrophage, originates primarily from the endocytosis/exocytosis process  
51 and should be considered to be a DAMP. In fact, this elucidation of the origin and inflammation-  
52 induced mechanisms associated with sCD14 contributes to our understanding of maintained  
53 tissue inflammation.

54  
55 **Key words:** inflammation, cystic fibrosis, NF- $\kappa$ B, inflammasome

56  
57  
58  
59

## 60 INTRODUCTION

61  
62 CD14 was first characterized as a membrane-associated GPI-anchored protein and a cell surface  
63 differentiation marker that is present on the surface of monocytes, macrophages, dendritic cells  
64 and neutrophils (1–5). CD14 acts as a receptor for bacterial LPS in cooperation with TLR-4 and -  
65 2 (5, 6) and can bind various bacterial ligands and receptors on phagocytes, thereby mediating the  
66 phagocytosis of bacteria and the clearance of apoptotic cells (4, 7–9). CD14 also exists as two  
67 soluble forms: a form with a low molecular mass of 48-50 kDa and a form with a high molecular  
68 mass of 53-56 kDa. The mechanisms of CD14 production have been reported to be linked to  
69 neosynthesis, proteolytic or GPI-tail cleavage by phospholipases or endocytosis/exocytosis (2, 3,  
70 10–18). In cells that express membrane CD14, including mononuclear cells, high concentrations  
71 of sCD14 are able to inhibit LPS-mediated functional responses (19, 20). In cells that lack  
72 membrane CD14, including most epithelial and endothelial cells, sCD14 enables these cells to  
73 respond to LPS (8, 21). At the local site of infection, pro-inflammatory signals that result from  
74 sCD14 can be protective, leading to local clearance of invading bacteria. However, widespread  
75 infection and activation of this pro-inflammatory signaling pathway can cause fatality through  
76 sepsis (22, 23). Furthermore, significant levels of sCD14 were detected in both serum and  
77 bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome (24). In  
78 addition, it was demonstrated in a murine model that *Streptococcus pneumoniae* uses sCD14 in  
79 the bronchoalveolar space to cause invasive respiratory tract infections (25). Overall, sCD14  
80 appears to act as a key component during pulmonary inflammation/infection.

81  
82 Chronic bacterial airway infection and subsequent intense neutrophilic inflammation with the  
83 release of intracellular proteases are considered to be the main contributors to bronchiectasis and  
84 end-stage lung disease CF patients. Recent research highlighted the worsening role of  
85 inflammation and immune responses in CF airway disease (26). Macrophages are antigen-  
86 presenting phagocytes that secrete pro-inflammatory mediators and antimicrobial factors in  
87 response to challenge by extracellular pathogens. Recently, several studies showed that specific  
88 features of macrophage activation in CF patients play an important role during the CF disease  
89 process (27–29). In our previous work, we observed an increase in sCD14 secretion by peripheral  
90 monocyte-derived macrophages from stable adult CF patients (29). However, the origin and

91 involvement of sCD14 has not been studied. In this work, we examined the mechanisms involved  
92 in the release of sCD14 by peripheral monocyte-derived macrophages from adult with CF and the  
93 inflammatory signaling pathways that are induced by sCD14 in non CF cells.

94

## 95 MATERIALS AND METHODS

96

### 97 CF patients

98 The experiments were conducted according to the Good Clinical Practice guidelines (Kong,  
99 1997) and approved by the Ethics Committee for human subjects of Rennes University Hospital  
100 (France, Ethics No. 11/38-827). All patients included in this study gave written informed consent.  
101 Sixty stable adult patients with CF were recruited at the '*Centre de Ressources et de*  
102 *Compétences pour la Mucoviscidose*' of Rennes University Hospital (France). The CF patients  
103 considered for inclusion were Caucasian and included 27 males and 33 females, who were aged  
104 between 18 and 52 years (mean age:  $30 \pm 9$ ). The CF diagnosis was based on typical clinical  
105 manifestations of the disease and confirmed by positive sweat tests and by CFTR gene mutation  
106 detection. Stable patients were defined by the absence of changes in symptoms in the 3 months  
107 prior to the study. All patients with CF received medication at the time of blood collection,  
108 including azithromycin (27%), aerosol DNase (48%), inhaled corticosteroids (72%) and azole  
109 therapy (47%). Oral corticosteroid therapy at the time of blood collection was an exclusion  
110 criterion, as this therapy may influence inflammatory phenotypes. Patients with the G551D  
111 mutation were not treated with ivacafor at the time of their participation in the study (except for  
112 patient 19, supplemental Table 1). The clinical features of the patients are reported in  
113 supplemental Table 1. According to the FEV1 values (% predicted), the majority of our patients  
114 (41/60) had mild to moderate lung disease (FEV1 values  $\geq 55\%$ ). In their sputum samples, 32  
115 patients had microbiological evidence of *Pseudomonas aeruginosa*, and *Staphylococcus aureus*  
116 and *Aspergillus fumigatus* were detected in 45 and 29 patients, respectively. The CF genotypes  
117 were representative of the French CF population, with 57% of participants having  
118 F508del/F508del mutations, 36% of patients having F508del/other mutations and 7% of patients  
119 having no F508del mutations (30). Blood monocyte counts were within the normal range, with a  
120 median number of  $0.679 \times 10^9/L$  (range  $0.23-1.12 \times 10^9/L$ ).

121

### 122 Cell cultures and treatments

123 Leukocytes were isolated by Ficoll gradient centrifugation, as described previously (31).  
124 Peripheral blood mononuclear cells from healthy non-CF subjects (written consent for the use of

125 blood samples for the research protocol was obtained, according to the regulation for blood  
126 transfusion of the French blood organization EFS, Rennes) were seeded according to the specific  
127 blood count of each subject. Monocytes, which were selected *via* a 1-hour adhesion step, were  
128 differentiated for 6 days using GM-CSF (400 UI/ml, Genzyme, Lyon, France) in RPMI 1640  
129 medium supplemented with 2 mM glutamine, antibiotics and 10% FBS (Lonza, Levallois Perret,  
130 France). Before treatment, the macrophages were placed in medium without serum for 24 hours.  
131 To study proteolytic origin of sCD14, non-CF macrophages were treated by e64d (1  $\mu$ M, Sigma-  
132 Aldrich, Saint-Quentin Fallavier, France), pepstatin A (1  $\mu$ M, Sigma-Aldrich, Saint-Quentin  
133 Fallavier, France), EDTA (0.1 mM, Sigma-Aldrich, Saint-Quentin Fallavier, France) or aprotinin  
134 (0.3  $\mu$ g/ml, Sigma-Aldrich, Saint-Quentin Fallavier, France) for 24 hours. To study GPI-tail  
135 cleavage by phospholipase, PI-PLC (1 U/ml, Life Technologies, ThermoFisher Scientific, Saint  
136 Aubin, France) was added to non-CF macrophages for 2 hours in the absence or presence of the  
137 PI-PLC inhibitor U-73122 (12.5  $\mu$ M, 1-hour pretreatment, Bertin Pharma, Montigny le  
138 Bretonneux, France). In parallel, macrophages from CF patients were treated with U-73122 for  
139 24 hours. To study membrane trafficking pathways, the cells were supplemented with water-  
140 soluble cholesterol (15 to 30  $\mu$ g/ml, 1-hour pretreatment, followed by 24 hours, Sigma-Aldrich,  
141 Saint-Quentin Fallavier, France) or with brefeldin A (100 ng/ml, 1-hour pretreatment, followed  
142 by 2 h, Cell Signaling Technology, Ozyme, Saint Quentin en Yvelines, France). To study  
143 inflammatory signaling pathways, human recombinant sCD14 protein (500 ng/ml, <0.1 EU/ $\mu$ g  
144 endotoxin, Sigma-Aldrich, Saint-Quentin Fallavier, France) was added to non-CF macrophages  
145 for 24 hours in the absence or presence of Bay 11-7082 (1 and 10  $\mu$ M, 1-hour pretreatment,  
146 Calbiochem, Merck Millipore, Molsheim, France) or the caspase inhibitor Z-WEHD-FMK (1 to  
147 30  $\mu$ M, 30-min pretreatment, Calbiochem, Merck Millipore, Molsheim, France). To study TLR  
148 involvement in the inflammatory effect of sCD14, sCD14 was added to non-CF macrophages in  
149 the presence of the TLR-4 antagonist LPS-RS (LPS from the photosynthetic bacterium  
150 *Rhodobacter sphaeroides*, 2  $\mu$ g/ml, InvivoGen, Toulouse, France), a CD14-neutralizing antibody  
151 (anti-hCD14 IgA, 10  $\mu$ g/ml, 1-hour pretreatment, InvivoGen, Toulouse, France), a TLR4-  
152 neutralizing antibody (anti-hTLR4 IgA, 10  $\mu$ g/ml, 1-hour pretreatment, Invitrogen, ThermoFisher  
153 Scientific, Saint Aubin, France) or control IgG2a (10  $\mu$ g/ml, 1-hour pretreatment, InvivoGen,  
154 Toulouse, France). At the doses used, the treatments did not affect the viability of the  
155 macrophages (data not shown). Viability was measured using the CellTiter 96® AQueous One



156 Solution Cell Proliferation Assay (Promega, charbonnières les bains, France) according to the  
157 instructions provided by the manufacturer.

158

### 159 **Gene expression**

160 RNA expression was analyzed using RT-qPCR assays. Briefly, total RNA was isolated from CF  
161 macrophages using NucleoSpin® RNA XS (Macherey Nagel, Hoerdt, France) and from non-CF  
162 macrophages using the PureLink RNA Mini Kit (Ambion®, ThermoFisher Scientific, Saint  
163 Aubin, France). The total RNA (1 µg) was reverse transcribed into cDNA using the High  
164 Capacity cDNA Reverse Transcription Kit (Applied Biosystems ThermoFisher Scientific, Saint  
165 Aubin, France). Real-time PCR was performed using the Power SYBR Green PCR Master kit  
166 (Applied Biosystems ThermoFisher Scientific, Saint Aubin, France) according to the  
167 manufacturer's instructions and an ABI Prism 7300 detector (Applied Biosystem ThermoFisher  
168 Scientific, Saint Aubin, France). The gene-specific primers for 18S, CD14, IL-1β, IL-8 were  
169 Quantitect®Primer Assay primers obtained from Qiagen (Hilden, Germany). The gene-specific  
170 primers for 18S, TNF, MMP-9, MMP-12, Cathepsin B, Cathepsin D, Cathepsin F, Cathepsin K,  
171 Cathepsin S, ADAM-9, ADAM-10, ADAM-12, ADAM-17, and PLCγ were purchased from  
172 Eurogentec (Liège, Belgium). A list of the primer sequences used for the RT-qPCR analysis is  
173 reported in supplemental Table 2. The amplification curves of the PCR products were analyzed  
174 with the ABI Prism SDS software using the comparative cycle threshold (CT) method. Relative  
175 gene expression was calculated by comparing the number of thermal cycles that were necessary  
176 to generate threshold amounts of product (CT). The CT was calculated for the each gene and for  
177 the housekeeping gene 18S. For each cDNA sample, the 18 S CT was subtracted from the CT for  
178 each gene to yield the ΔCT, thus normalizing the initial amount of RNA used. The amount of  
179 mRNA was calculated as  $2^{-\Delta\Delta CT}$ , where the ΔΔCT is the difference between the ΔCT of the two  
180 cDNA samples to be compared. The data from CF samples are expressed relative to the mRNA  
181 level found in non-CF samples. The data from the treatment samples are expressed relative to the  
182 mRNA level found in the controls.

183

### 184 **Cytokine/chemokine, sCD14 and NFκB p65 level quantification**

185 IL-1 $\beta$ , IL-8, TNF- $\alpha$  and sCD14 levels were measured in the supernatants of the cell cultures and  
186 in plasma from CF patients using a DuoSet<sup>®</sup> ELISA kit (R&D system, Abingdon, United  
187 Kingdom), according to the instructions provided by the manufacturer. The NF $\kappa$ B p65 level was  
188 measured in the nuclear fraction of cell cultures using TransAM<sup>®</sup> NF $\kappa$ B p65 (Active Motif, La  
189 Hulpe, Belgium), according to the instructions provided by the manufacturer.

190

### 191 **Neosynthesis measurement**

192 Soluble CD14 neosynthesis was measured using Click-IT<sup>®</sup> technology (Thermo-fischer  
193 scientific). Macrophages were placed in RPMI 1640 medium without methionine (Gibco,  
194 ThermoFisher Scientific, Saint Aubin, France). After 30 min incubation (37°C, 5% CO<sub>2</sub>),  
195 macrophages were pulse-chase labeled in the presence of Click-IT<sup>®</sup> L- Azidohomoalanin  
196 (50 $\mu$ M; Molecular Probes, ThermoFisher Scientific, Saint Aubin, France) in RPMI 1640 medium  
197 without methionine for 3 hours. Afterwards, medium was changed by RPMI 1640 with  
198 methionine and macrophages were incubated for 21 hours (37°C, 5% CO<sub>2</sub>). Then supernatants  
199 were recovered and analyzed for sCD14 level quantification using DuoSet<sup>®</sup> ELISA kit (R&D  
200 system, Abingdon, United Kingdom). . To measure neosynthesis, biotin-coupled detection  
201 antibody was substituted by Click-IT<sup>®</sup> Biotin DIBO Alkyne (Molecular Probes, ThermoFisher  
202 Scientific, Saint Aubin, France), for copper-free click chemistry.

203

### 204 **Cholesterol level quantification**

205 Total lipids were extracted with 200  $\mu$ l CHCl<sub>3</sub>/MeOH/NP-40 (7:11:0.1; v/v). The sample was  
206 centrifuged for 10 min at 14,000 rpm. The chloroformic layer was evaporated to dryness under a  
207 nitrogen stream. Then, the free cholesterol levels was determined using Cholesterol/Cholesteryl  
208 Ester Quantitation Kit (Merck Millipore, Molsheim, France), according to the instructions  
209 provided by the manufacturer. Cholesterol is oxidized by cholesterol oxidase to yield H<sub>2</sub>O<sub>2</sub>. The  
210 resulting H<sub>2</sub>O<sub>2</sub> interacts with a sensitive cholesterol probe to produce resorufin, which can be  
211 detected by spectrophotometrically 570 nm. Total protein concentrations were determined using a  
212 BCA protein assay kit (Thermoscientific, Saint Aubin, France) to express cholesterol based on  
213 the protein concentration for each sample.

214

215 **Zymography assay**

216 The gelatinolytic activity of secreted MMP-9 was analyzed using gelatin zymography, as  
217 described previously (32). The samples were subjected to electrophoresis via 10% SDS-PAGE  
218 containing 1 mg/ml of gelatin (Sigma Aldrich, Saint-Quentin Fallavier, France) under non-  
219 reducing conditions. After electrophoresis, the gels were washed twice with 2.5% Triton X-100,  
220 rinsed with water, and incubated at 37°C overnight in reaction buffer (50 mM Tris, 5 mM CaCl<sub>2</sub>,  
221 and 2.1 mM ZnCl<sub>2</sub>, pH 8.0). The gels were stained with Coomassie brilliant blue (Sigma Aldrich,  
222 Saint-Quentin Fallavier, France) and de-stained in a solution of 25% ethanol and 10% acetic acid.  
223 Gelatinase activity appeared as clear bands against a blue background. The molecular weights of  
224 the gelatinolytic bands were estimated using a prestained protein ladder (10 - 250 kDa,  
225 Euromedex, Souffelweyersheim, France). Images of the zymograms were acquired using the Gel  
226 Doc 1000 Gel Documentation System (Bio-Rad laboratories, Marnes-La –Coquette, France), and  
227 both the surface and intensity of the lysis bands were quantified by densitometry using the  
228 MultiGauge software (Fujifilm, Tokyo, Japan).

229

230 **Gene silencing by siRNA**

231 ON-TARGETplus siRNAs against NLRC4 or NLRP3 were synthesized and annealed by  
232 Dharmacon RNAi Technologies (ThermoFisher Scientific, Saint Aubin, France). siRNA  
233 duplexes were transfected using the Lipofectamine RNAiMAX Reagent (Life Technologies,  
234 ThermoFisher Scientific, Saint Aubin, France). The transfection reagent and siRNAs were mixed,  
235 and complex formation was allowed to proceed for 5 min at room temperature before the  
236 complex was added to the macrophages. After 72 hours, the cells were treated or not treated with  
237 sCD14 (500 ng/ml, 24 hours) before being harvested for analysis.

238

239 **Immunoblotting**

240 Membrane-bound proteins were extracted from the macrophages by lysing the cells with RIPA  
241 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton-X100,  
242 12 mM deoxycholate, 2 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM PMSF, cOmplete™ EDTA-free  
243 Protease Inhibitor Cocktail (Roche, Bâle, Switzerland) and PhosSTOP Phosphatase Inhibitor  
244 Cocktail (Roche, Bâle, Switzerland). The macrophages were incubated at 4°C for 30 minutes in  
245 lysis buffer with vortexing for 30 seconds every 10 minutes. The supernatant containing proteins

246 was obtained by subsequent centrifugation at 10,000 g for 10 minutes at 4°C, and the protein  
247 concentration was determined using a BCA protein assay kit (ThermoFisher Scientific, Saint  
248 Aubin, France). Proteins were separated via SDS-PAGE and transferred to a nitrocellulose  
249 membrane. Then, the membrane was subjected to western blotting using a rabbit anti-IκBα, rabbit  
250 anti-P-IκBα, rabbit polyclonal anti-Caspase 1, mouse anti-IL-1β, rabbit anti-NLRP3, rabbit anti-  
251 NLRC4 (Cell Signaling Technology, Ozyme, Saint Quentin en Yvelines, France), rabbit anti-  
252 CD14 (Epitomics, Burlingame, CA, US) or mouse anti-HSC70 (Santa Cruz, Heidelberg,  
253 Germany) antibodies. Horseradish peroxidase-conjugated goat anti-rabbit (Cell Signaling  
254 Technology, Ozyme, Saint Quentin en Yvelines, France) or goat anti-mouse (Dako, Les Ulis,  
255 France) antibodies were used as secondary antibodies, and proteins were detected using enhanced  
256 chemiluminescence. The images were scanned with the Fujifilm LAS-3000 imager (Fujifilm,  
257 Tokyo, Japan) and analyzed with the MultiGauge software (Fujifilm, Tokyo, Japan) for  
258 densitometry. The intensity of the bands was normalized based on HSC-70.

259

## 260 **Statistical analysis**

261 The number of subjects and experiments used in each group is stated in the respective figures.  
262 Statistical significance was evaluated by using the GraphPad Prism software v.6.0 (GraphPad  
263 Software Inc., San Diego, CA, US). A non-parametric Mann-Whitney test was used to assess the  
264 statistical significance of differences between non-CF and CF groups. A parametric ratio  
265 Student's t-test was used to assess statistical significance between treatments. For each analysis, a  
266 p-value <0.05 was considered to be significant.

267

268 **RESULTS**

269

270 **Origin of sCD14 in human CF macrophages**

271

272 We previously observed the overproduction of sCD14 in the supernatant of macrophages from  
273 stable adult patients with CF (29). However, plasma levels of sCD14 do not differ between stable  
274 adult CF patients and healthy subjects (Fig. 1A).

275

276 To elucidate the molecular mechanisms that underlie the production of the soluble form of CD14  
277 in human CF macrophages, we studied several hypotheses based on the literature. It was reported  
278 that sCD14 could be generated by different mechanisms, including the endocytosis of mCD14,  
279 the cleavage of the GPI anchor by PI-PLC, direct proteolytic cleavage from the cell surface and  
280 neosynthesis.

281

282 To explore the neosynthesis hypothesis, we examined the regulation of CD14 production at the  
283 mRNA level in CF and non-CF macrophages. We found that CD14 mRNA levels were similar  
284 between CF and non-CF macrophages (Fig. 1B). Furthermore, pulse chase experiments with  
285 Click-IT® L- Azidohomoalanin showed no differences in neosynthesis of sCD14 between non-  
286 CF and CF macrophages whereas we demonstrated an increase of total sCD14 production in  
287 supernatant of CF macrophages (Fig. 1C). Thus, neosynthesis can be ruled out as a mechanism.

288

289 sCD14 may be formed by direct proteolytic cleavage from the cell surface. However, the  
290 inhibitors of metalloproteases (EDTA, Fig. 2A), cysteine proteases (e64d, Fig. 2D), aspartic  
291 proteases (pepstatin A, Fig. 2E) or serine proteases (aprotinin, Fig. 2F) did not influenced sCD14  
292 production. Furthermore, the gene expression of the metalloproteases MMP-9 (Fig. 2B), MMP-12  
293 (Supplemental Fig. 1A), ADAM-9, -10, -12, 17 (Supplemental Fig. 1B to 1E) and cathepsins B,  
294 D, F, K and S (Supplemental Fig. 1F to 1J) in CF macrophages is decreased. Moreover, the  
295 latent form of the MMP-9 protein and supernatant MMP-9 activity, as measured by zymography,  
296 are decreased in CF *vs.* non-CF macrophages (Fig. 2C). The protease cleavage hypothesis is  
297 excluded by these results.

298

299 The main hypothesis concerning sCD14 generation is the cleavage of the GPI tail by PI-PLC. We  
300 investigated this hypothesis by exposing non-CF macrophages to PI-PLC (1 U/ml) with or  
301 without its inhibitor, U-73122 (12.5  $\mu$ M). We observed that PI-PLC significantly increased the  
302 production of sCD14 by non-CF macrophages and that this effect was inhibited by U-73122 (Fig.  
303 3A). However, the treatment of CF macrophages with U-73122 did not inhibit the increased  
304 secretion of sCD14 into their supernatant (Fig. 3B). Furthermore, the expression of the PLC gene  
305 does not differ between non-CF and CF macrophages (Supplemental Fig. 1G). Indeed, PI-PLC  
306 participates in the production of sCD14 in non-CF macrophages but has no role in sCD14  
307 overproduction from CF macrophages.

308  
309 Cholesterol has been reported to increase sCD14 secretion through the endocytosis and  
310 subsequent cleavage of mCD14. Furthermore cholesterol is increased in CF macrophages (Fig.  
311 4A). Thus, we investigated the effect of water-soluble cholesterol supplementation in non-CF  
312 macrophages. The results presented in Fig. 4B show that sCD14 production by non-CF  
313 macrophages is increased by supplementation with water-soluble cholesterol (15  $\mu$ g/ml). By  
314 modulating membrane lipid composition, cholesterol could be involved in the production of  
315 sCD14 in CF macrophages.

316 The fungal metabolite brefeldin A blocks forward protein transport between the ER and the Golgi  
317 complex but not retrograde transport (33). Incubation with brefeldin A decreased sCD14  
318 secretion in non-CF and CF macrophages, implicating the secretory ER/Golgi pathway in sCD14  
319 secretion in CF (Fig. 4C).

320

### 321 **Function of human recombinant sCD14 in human macrophages**

322

323 To evaluate the inflammatory role of sCD14 in human non-CF macrophages, we used human  
324 recombinant sCD14 (hr-sCD14), which did not affect the viability of the cells (data not shown).

325

326 We had to check the effect of human recombinant sCD14 on the NF $\kappa$ B activation, which is  
327 required for cytokine/chemokine production. In fact, the mean concentration of sCD14 in CF  
328 macrophage supernatants was 14.68 ng/ml per  $2 \times 10^6$  cells/well (Fig. 3B), which corresponds to  
329 220 ng/ml per  $30 \times 10^6$  cells, in comparison to the mean level of sCD14 observed in non-CF

330 macrophage supernatants, which was 2.35 ng/ml per  $30 \times 10^6$  cells/well (Fig. 4B). Indeed, we used  
331 increasing concentrations of human recombinant sCD14 (1, 10, 100 and 500 ng/ml on  $30 \times 10^6$   
332 non-CF cells/well) to evaluate its inflammatory role in macrophages.

333  
334 To determine whether sCD14 has an inflammatory effect, we investigated the production of pro-  
335 inflammatory cytokine/chemokine by non-CF macrophages exposed to sCD14. Treatment with  
336 sCD14 significantly increased IL-1 $\beta$ , IL-8 and TNF- $\alpha$  gene expressions at 6 hours and secreted  
337 levels at 24 hours in a dose-dependent manner (Fig. 5A and 5B). The effects on gene expression  
338 were maintained at 24 hours (Fig. 5A). These results show that sCD14 could participate in  
339 chronic inflammation by promoting pro-inflammatory cytokine/chemokine secretion.  
340 Furthermore, sCD14 potentiates LPS-induced cytokine/chemokine production by non-CF  
341 macrophages (Supplemental Fig. 2).

342  
343 The NF- $\kappa$ B pathway is one of the pathways involved in cytokine expression. We studied NF- $\kappa$ B  
344 activation after sCD14 treatment in non-CF macrophages. The results showed the  
345 phosphorylation of I $\kappa$ B $\alpha$  at 10 min, concomitant with a decrease in the I $\kappa$ B $\alpha$  protein and a time-  
346 dependent translocation of the NF $\kappa$ B p65 subunit to the nucleus (Fig. 6A and 6B). Indeed, the  
347 NF- $\kappa$ B pathway is activated by sCD14 in non-CF macrophages. To determine whether this  
348 activation is related to the expression and secretion of inflammatory cytokines, we pretreated  
349 non-CF macrophages with an inhibitor of NF- $\kappa$ B, Bay 11-7082. Bay 11-7082, which is a  
350 potential anti-inflammatory agent, is an irreversible inhibitor of IKK $\alpha$  and cytokine-inducible  
351 I $\kappa$ B $\alpha$  phosphorylation that does not affect constitutive phosphorylation (34). A significant  
352 decrease in IL-1 $\beta$ , TNF- $\alpha$  and IL-8 gene expressions and secreted levels was observed with Bay  
353 11-7082 (Fig. 6C and 6D). These results show that the NF- $\kappa$ B pathway participates in the pro-  
354 inflammatory cytokine/chemokine production induced by non-CF macrophages sCD14 treatment.

355  
356 Unlike other pro-inflammatory cytokines, IL-1 $\beta$  production is tightly regulated by a unique two-  
357 signal mechanism. The primary signal induces the expression of pro-IL-1 $\beta$  and is mediated in  
358 part by NF- $\kappa$ B activation. The secondary signal activates the NLR-subset inflammasome  
359 intracellular signaling complexes, which are composed of NLRs, pro-caspase 1, and the adaptor

360 protein ASC. The formation of the inflammasome complex results in the proteolytic cleavage of  
361 pro-caspase 1 to yield active caspase 1, which in turn cleaves pro-IL-1 $\beta$ , producing mature and  
362 active IL-1 $\beta$ . To determine if caspase 1 could be involved in IL-1 $\beta$  processing in response to  
363 sCD14, we investigated caspase 1 expression and activation. Macrophage exposure to sCD14  
364 induced early caspase 1 cleavage starting after 5 min through the early production of pro-caspase  
365 1 and the appearance of cleaved caspase 1 (Fig. 7A). This cleavage is followed by the subsequent  
366 secretion of IL-1 $\beta$  by macrophages starting after 120 min (Fig. 7B). To investigate the  
367 involvement of caspase 1 in IL-1 $\beta$  secretion after sCD14 treatment, we pre-incubated non-CF  
368 macrophages with the caspase 1 specific inhibitor Z-WEHD-FMK. The caspase 1 inhibitor  
369 abolished IL-1 $\beta$  secretion by non-CF macrophages (Fig. 7C). All of these results showed that IL-  
370 1 $\beta$  production in response to sCD14 involves the caspase 1 pathway.

371  
372 Caspase 1 pathway activation requires a specific platform called the inflammasome complex.  
373 However, various inflammasome complexes are formed depending on the stimulus. Concerning  
374 the inflammasome complex in macrophages, the most frequently involved stimuli are flagellin or  
375 LPS. We investigated the NLRC4 and NLRP3 inflammasome complexes by using RNA  
376 interference. The efficiency of transfection of NLRC4 siRNA and NLRP3 siRNA was assessed  
377 via western blotting of the total protein fraction from non-CF macrophages. Specific siRNAs  
378 directed against NLRC4 and NLRP3 turned off NLRP3 and NLRC4 protein expression in  
379 macrophages, respectively (Fig. 8A and 8B). Furthermore, while transfection with NLRP3 siRNA  
380 or NLRC4 siRNA had no significant effect on IL-1 $\beta$  secretion, in macrophages treated with  
381 sCD14, transfection with each siRNA significantly decreases IL-1 $\beta$  secretion (Fig. 8C). These  
382 results suggested that both inflammasome platforms (NLRC4 and NLRP3) participate in the  
383 induction of IL-1 $\beta$  secretion in response to sCD14 exposure.

384  
385 In view of the mechanisms described above, the TLR-4 receptor and its signaling pathways  
386 should be involved in the effects induced by sCD14 in macrophages. To efficiently neutralize the  
387 biological activity of sCD14, non-CF macrophages were pre-incubated with a CD14-neutralizing  
388 antibody, resulting in decreased IL-8, TNF- $\alpha$  and IL-1 $\beta$  levels in the cell supernatants (Fig. 9).  
389 Moreover, the pretreatment of non-CF macrophages with an antagonist of TLR-4 (LPS-RS)



390 strongly inhibited the TNF- $\alpha$ , IL-8 and IL-1 $\beta$  production induced by sCD14 (Fig. 9). Finally to  
391 neutralize TLR4, non-CF macrophages were pre-incubated with a TLR4-neutralizing antibody,  
392 resulting in decreased IL-8 and TNF- $\alpha$  levels in the cell supernatants. Treatment with sCD14 did  
393 not modify the membrane expression of TLR-4, as measured by flow cytometry, showing that  
394 TLR-4 is not endocytosed after activation (data not shown). In this context, TLR-4 should be  
395 involved in the inflammatory effect of sCD14.

396 **DISCUSSION**

397  
398 Macrophages coordinate inflammatory responses by secreting cytokines and chemokines that are  
399 responsible for diverse physiological effects that are important in the pathogenesis of CF and  
400 result in chronic infection/inflammation (35–37).

401  
402 In a previous study, we observed an increase in cytokine/chemokine production in CF  
403 macrophage supernatants and particularly strong secretion of sCD14 (29). Elevated  
404 concentrations of sCD14 were also found in serum from patients with bacterial infections (38, 39)  
405 or pneumonia (40), as well as in other chronic inflammatory diseases, such as lupus  
406 erythematosus (41). However, we did not observe elevated sCD14 levels in plasma from stable  
407 adult CF patients, showing that sCD14 is not a systemic marker in CF, as previously observed in  
408 the plasma of children with CF (40).

409  
410 It has been previously shown that sCD14 could be generated by several mechanisms, which  
411 include neosynthesis, direct proteolytic cleavage from the cell surface, cleavage of the GPI  
412 anchor by phospholipases and endocytosis/exocytosis (2, 3, 10–18). In our study, CD14 gene  
413 expression was the same in CF and non-CF macrophages. Moreover, no neosynthesis of sCD14  
414 was observed in CF macrophage. Indeed, the elevated sCD14 levels observed in CF macrophage  
415 supernatants cannot be explained by an increase in gene expression and synthesis. Proteases,  
416 metalloproteases and/or cathepsins have been demonstrated to be present in large amounts in CF  
417 airways (42). However, the gene expression of MMPs, ADAMs as well as cathepsins is lower in  
418 CF macrophages than in non-CF macrophages. Furthermore, MMP-9 and its activity are also  
419 decreased in CF macrophage supernatants. Regarding these data, the origin of sCD14 in human  
420 CF macrophages was not direct proteolytic cleavage from the cell surface, as reported previously,  
421 explaining the increase in plasma sCD14 that occurs during sepsis (43). Cleavage of the GPI  
422 anchor by phospholipases is also suggested to explain sCD14 release. In our study, PI-PLC  
423 induced increased production of sCD14 in non-CF macrophage supernatants. The PI-PLC  
424 inhibitor reversed this effect but not the sCD14 overproduction observed in CF macrophages.  
425 Thus, PI-PLC participates in the production of sCD14 in non-CF macrophages but has no role in  
426 sCD14 overproduction in CF macrophages. Finally, the hypothesis that involves the

427 endocytosis/exocytosis of CD14 was considered. The depletion of cholesterol from the plasma  
428 membrane has been shown to affect endocytosis and protein sorting (44). As an example,  
429 cholesterol perturbation by filipin led to the redistribution of GPI-GFP from the cell surface to the  
430 Golgi complex (45), and the supplementation of the medium with cholesterol allowed the  
431 transport of secretory membrane proteins from the ER to the Golgi (46). In our study, cholesterol  
432 level is higher in CF than in non-CF macrophages and cholesterol supplementation in non-CF  
433 macrophages increased sCD14 secretion by macrophages. Furthermore, other work has shown  
434 that the inhibition of cholesterol synthesis by lovastatin decreased sCD14 production in RAW  
435 264.7 macrophages (47). Endocytosis/exocytosis appears to be a suitable hypothesis because the  
436 use of brefeldin A to block forward transport between the ER and the Golgi complex decreases  
437 sCD14 secretion in CF macrophages.

438  
439 It is well established that sCD14 alone is not sufficient to promote inflammation, except in cells  
440 that do not express mCD14, but the presence of sCD14 can enhance the sensitivity of monocytes  
441 and macrophages to LPS or lipopeptide by several orders of magnitude (48). In our study, we  
442 show that treatment with sCD14 alone enhances the induced inflammatory response and the  
443 effects of LPS by stimulating the secretion of IL-8, TNF- $\alpha$  and IL-1 $\beta$  in non-CF macrophages.  
444 However, one question remains to be answered: how can sCD14 induce the production of these  
445 inflammatory cytokines and chemokines?

446  
447 Therefore, CD14 is assumed to function as a multi-ligand pattern recognition receptor by  
448 recognizing and binding to different PAMPs and DAMPs (49). In combination with the TLRs  
449 proteins, CD14 is an important mediator of innate immune responses to infection (5, 8).  
450 Membrane CD14 is a co-receptor for endotoxin through TLR-4 trans-membrane signaling, both  
451 at the cell surface and within the endosomal compartment. TLR-4 has been shown to contribute  
452 to the PAMP response of human cells, and its activation results in a pathway based on the  
453 activation of TIR-containing adaptor molecules: the rapid TIRAP/MyD88 pathway, which  
454 activates NF- $\kappa$ B and MAPK, resulting in the expression of pro-inflammatory cytokines and  
455 chemokines (50). In human monocyte-derived macrophages, sCD14 promoted the  
456 phosphorylation of I $\kappa$ B $\alpha$ , allowing the activation of NF- $\kappa$ B. Bay 11-7082, which is a potential  
457 anti-inflammatory agent and an irreversible inhibitor of IKK $\alpha$  and I $\kappa$ B $\alpha$  phosphorylation,

458 diminished sCD14-elicited IL-8, TNF- $\alpha$  and IL-1 $\beta$  expression and secretion, suggesting a role for  
459 NF $\kappa$ B signaling in sCD14-dependent macrophage inflammation. Furthermore, macrophage  
460 activation with sCD14 induces the activation of pro-caspase 1, leading to the cleaved and active  
461 form of caspase 1. Next, pro-IL-1 $\beta$  is cleaved by caspase 1, and IL-1 $\beta$  mature is secreted in  
462 macrophage supernatants; this effect is inhibited by Z-WEHD-FMK, which is a specific caspase  
463 1 inhibitor. The activation of caspase 1 involves inflammasome complex formation, which  
464 requires NLRs. NLRs are pattern recognition receptors and play key roles in the regulation of the  
465 innate immune response in cooperation with TLRs. Among the NLRs, NLRC4 and NLRP3  
466 appear to be the most involved in this response. The infection of macrophages with several  
467 Gram-negative bacteria, including *Pseudomonas aeruginosa*, which currently infects CF patients,  
468 activates caspase 1 through NLRC4 (51). The activation of caspase 1 through NLRP3 is induced  
469 by DAMPs, such as K<sup>+</sup> efflux, ATP via P2XR7, ROS, and cathepsin D from lysosome damage  
470 (52). We turned off NLRC4 and NLRP3 protein expression using specific siRNAs directed  
471 against NLRC4 or NLRP3. The treatment of macrophages with NLRP3 siRNA or NLRC4  
472 siRNA abolished IL-1 $\beta$  secretion, suggesting that both inflammasome platforms (NLRC4 and  
473 NLRP3) induce IL-1 $\beta$  secretion in response to sCD14 exposure. Altogether, our data suggest that  
474 sCD14 acts as a DAMP in macrophages. In fact, extracellular sCD14 can bind membrane  
475 proteins or phospholipids (53) that could be responsible for inflammatory cytokine production.  
476 An anti-CD14 neutralizing antibody is able to inhibit the sCD14-induced synthesis of TNF- $\alpha$ , IL-  
477 8 and IL-1 $\beta$ . To explore the action of sCD14 via the TLR-4 receptor, we used a potent antagonist  
478 of this receptor LPS-RS and an anti-TLR4 antibody, which decreases partly sCD14-induced  
479 cytokine production in macrophages. Thus, part of the effect of sCD14 appears to be mediated by  
480 the CD14/TLR-4 complex. However, further investigations are needed to completely understand  
481 the molecular mechanisms involved in sCD14 signaling pathway in macrophages.

482  
483 In conclusion, numerous mechanisms concerning the origin of sCD14 were considered in this  
484 work, but in CF macrophages, the endocytosis/exocytosis process appears to be the main  
485 mechanism involved in sCD14 production. We propose that the overproduction of sCD14  
486 previously observed in macrophages from CF patients (29) should be considered to be a DAMP  
487 that can induce pro-inflammatory cytokine/chemokine production independent of LPS.

488 Moreover, sCD14 can also enhance the LPS response. Both of these effects are dependent on the  
489 TLR-4/CD14 membrane complex, NF- $\kappa$ B and the inflammasome. The characterization of the  
490 origin and inflammatory function of sCD14 presented in this paper is an important step in  
491 understanding chronic infection/inflammation. Furthermore, this study provides a novel approach  
492 to the development of anti-inflammatory therapeutics in CF.

493

494 **REFERENCES**

495

- 496 1. Bazil, V., Horejsi, V., Baudys, M., Kristofova, H., Strominger, J. L., Kostka, W., and  
497 Hilgert, I. (1986) Biochemical characterization of a soluble form of the 53-kDa monocyte  
498 surface antigen. *Eur. J. Immunol.* **16**, 1583–1589
- 499 2. Haziot, A., Chen, S., Ferrero, E., Low, M. G., Silber, R., and Goyert, S. M. (1988) The  
500 monocyte differentiation antigen, CD14, is anchored to the cell membrane by a  
501 phosphatidylinositol linkage. *J. Immunol.* **141**, 547–552
- 502 3. Simmons, D. L., Tan, S., Tenen, D. G., Nicholson-Weller, A., and Seed, B. (1989)  
503 Monocyte antigen CD14 is a phospholipid anchored membrane protein. *Blood* **73**, 284–289
- 504 4. Wright, S. D. (1995) CD14 and innate recognition of bacteria. *J. Immunol.* **155**, 6–8
- 505 5. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., and Mathison, J. C. (1990)  
506 CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.  
507 *Science* **249**, 1431–1433
- 508 6. Schütt, C. (1999) CD14. *Int. J. Biochem. Cell Biol.* **31**, 545–549
- 509 7. Gegner, J. A., Ulevitch, R. J., and Tobias, P. S. (1995) Lipopolysaccharide (LPS) Signal  
510 Transduction and Clearance. Dual roles for LPS binding protein and membrane CD14. *J.*  
511 *Biol. Chem.* **270**, 5320–5325
- 512 8. Pugin, J., Heumann, D., Tomasz, A., Kravchenko, V. V., Akamatsu, Y., Nishijima, M.,  
513 Glauser, M. P., Tobias, P. S., and Ulevitch, R. J. (1994) CD14 Is a pattern recognition  
514 receptor. *Immunity* **1**, 509–516
- 515 9. Schiff, D. E., Kline, L., Soldau, K., Lee, J. D., Pugin, J., Tobias, P. S., and Ulevitch, R. J.  
516 (1997) Phagocytosis of gram-negative bacteria by a unique CD14-dependent mechanism. *J.*  
517 *Leukoc. Biol.* **62**, 786–794
- 518 10. Bazil, V. and Strominger, J. L. (1991) Shedding as a mechanism of down-modulation of  
519 CD14 on stimulated human monocytes. *J. Immunol.* **147**, 1567–1574
- 520 11. Bufler, P., Stiegler, G., Schuchmann, M., Hess, S., Krüger, C., Stelter, F., Eckerskorn, C.,  
521 Schütt, C., and Engelmann, H. (1995) Soluble lipopolysaccharide receptor (CD14) is  
522 released via two different mechanisms from human monocytes and CD14 transfectants. *Eur.*  
523 *J. Immunol.* **25**, 604–610

- 524 12. Durieux, J.-J., Vita, N., Popescu, O., Guette, F., Calzada-Wack, J., Munker, R., Schmidt, R.  
525 E., Lupker, J., Ferrara, P., Ziegler-Heitbrock, H. W. L., and Labeta, M. O. (1994) The two  
526 soluble forms of the lipopolysaccharide receptor, CD14: Characterization and release by  
527 normal human monocytes. *Eur. J. Immunol.* **24**, 2006–2012
- 528 13. Stelter, F., Pfister, M., Bernheiden, M., Jack, R. S., Bufler, P., Engelmann, H., and Schütt,  
529 C. (1996) The Myeloid Differentiation Antigen CD14 is N- and O-Glycosylated. *Eur. J.*  
530 *Biochem.* **236**, 457–464
- 531 14. Thieblemont, N. and Wright, S. D. (1999) Transport of bacterial lipopolysaccharide to the  
532 Golgi apparatus. *J. Exp. Med.* **190**, 523–534
- 533 15. Kirkland, T. N. and Viriyakosol, S. (1998) Structure-function analysis of soluble and  
534 membrane-bound CD14. *Prog. Clin. Biol. Res.* **397**, 79–87
- 535 16. Bazil, V., Baudys, M., Hilgert, I., Stefanová, I., Low, M. G., Zbrozek, J., and Horejsí, V.  
536 (1989) Structural relationship between the soluble and membrane-bound forms of human  
537 monocyte surface glycoprotein CD14. *Mol. Immunol.* **26**, 657–662
- 538 17. Coyne, C. P., Howell, T., Smodlaka, H., Willetto, C., Fenwick, B. W., and Cheney, E.  
539 (2002) Alterations in membrane-associated CD14 expression and the simultaneous  
540 liberation of soluble CD14 fragment in adherent macrophages mediated by a leukocyte  
541 carboxyl/aspartate protease. *J. Endotoxin Res.* **8**, 273–283
- 542 18. Labeta, M. O., Durieux, J.-J., Fernandez, N., Herrmann, R., and Ferrara, P. (1993) Release  
543 from a human monocyte-like cell line of two different soluble forms of the  
544 lipopolysaccharide receptor, CD14. *Eur. J. Immunol.* **23**, 2144–2151
- 545 19. Haziot, A., Rong, G. W., Bazil, V., Silver, J., and Goyert, S. M. (1994) Recombinant  
546 soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in  
547 whole blood. *J. Immunol.* **152**, 5868–5876
- 548 20. Schütt, C., Schilling, T., and Krüger, C. (1991) sCD14 prevents endotoxin inducible  
549 oxidative burst response of human monocytes. *Allerg. Immunol. (Leipz.)* **37**, 159–164
- 550 21. Tapping, R. I. and Tobias, P. S. (2000) Soluble CD14-mediated cellular responses to  
551 lipopolysaccharide. *Chem. Immunol.* **74**, 108–121
- 552 22. Opal, S. M., Scannon, P. J., Vincent, J.-L., White, M., Carroll, S. F., Palardy, J. E., Parejo,  
553 N. A., Pribble, J. P., and Lemke, J. H. (1999) Relationship between Plasma Levels of

- 554 Lipopolysaccharide (LPS) and LPS-Binding Protein in Patients with Severe Sepsis and  
555 Septic Shock. *J. Infect. Dis.* **180**, 1584–1589
- 556 23. Salomao, R., Brunialti, M. K. C., Rapozo, M. M., Baggio-Zappia, G. L., Galanos, C., and  
557 Freudenberg, M. (2012) Bacterial sensing, cell signaling, and modulation of the immune  
558 response during sepsis. *Shock Augusta Ga* **38**, 227–242
- 559 24. Martin, T. R., Ruhenfeld, G., Steinberg, K. P., Hudson, L. D., Raghu, G., Moriarty, A. M.,  
560 Leturcq, D. J., Tobias, P. S., and Ulevitch, R. J. (1994) ENdotoxin, endotoxin-binding  
561 protein, and soluble cd14 are present in bronchoalveolar lavage fluid of patients with adult  
562 respiratory distress syndrome. *Chest* **105**, 55S – 56S
- 563 25. Dessing, M. C., Knapp, S., Florquin, S., de Vos, A. F., and van der Poll, T. (2007) CD14  
564 Facilitates Invasive Respiratory Tract Infection by *Streptococcus pneumoniae*. *Am. J.*  
565 *Respir. Crit. Care Med.* **175**, 604–611
- 566 26. Ratner, D. and Mueller, C. (2012) Immune Responses in Cystic Fibrosis. *Am. J. Respir. Cell*  
567 *Mol. Biol.* **46**, 715–722
- 568 27. Cifani, N., Pompili, B., Anile, M., Patella, M., Diso, D., Venuta, F., Cimino, G., Quattrucci,  
569 S., Di Domenico, E. G., Ascenzioni, F., and Porto, P. D. (2013) Reactive-Oxygen-Species-  
570 Mediated *P. aeruginosa* Killing Is Functional in Human Cystic Fibrosis Macrophages. *PLoS*  
571 *ONE* **8**, e71717
- 572 28. Del Porto, P., Cifani, N., Guarnieri, S., Di Domenico, E. G., Mariggìo, M. A., Spadaro, F.,  
573 Guglietta, S., Anile, M., Venuta, F., Quattrucci, S., and Ascenzioni, F. (2011) Dysfunctional  
574 CFTR Alters the Bactericidal Activity of Human Macrophages against *Pseudomonas*  
575 *aeruginosa*. *PLoS ONE* **6**, e19970
- 576 29. Simonin-Le Jeune, K., Le Jeune, A., Jouneau, S., Belleguic, C., Roux, P.-F., Jaguin, M.,  
577 Dimanche-Boitre, M.-T., Lecureur, V., Leclercq, C., Desrues, B., Brinchault, G., Gangneux,  
578 J.-P., and Martin-Chouly, C. (2013) Impaired Functions of Macrophage from Cystic  
579 Fibrosis Patients: CD11b, TLR-5 Decrease and sCD14, Inflammatory Cytokines Increase.  
580 *PLoS ONE* **8**, e75667
- 581 30. Bellis, G., Lemonnier, L., and Sponga, M. (2012) Registre Français de la Mucoviscidose.
- 582 31. Grevenynghe, J. van, Rion, S., Ferrec, E. L., Vee, M. L., Amiot, L., Fauchet, R., and Fardel,  
583 O. (2003) Polycyclic Aromatic Hydrocarbons Inhibit Differentiation of Human Monocytes  
584 into Macrophages. *J. Immunol.* **170**, 2374–2381



- 585 32. Martin-Chouly, C. A. E., Astier, A., Jacob, C., Pruniaux, M.-P., Bertrand, C., and Lagente,  
586 V. (2004) Modulation of matrix metalloproteinase production from human lung fibroblasts  
587 by type 4 phosphodiesterase inhibitors. *Life Sci.* **75**, 823–840
- 588 33. Miller, S., G., Carnell, L., and Moore, H.-P., H. (1992) Post-Golgi membrane traffic:  
589 brefeldin A inhibits export from distal Golgi compartments to the cell surface but not  
590 recycling. *J. Cell Biol.* **118**, 267–283
- 591 34. Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., and Gerritsen,  
592 M. E. (1997) Novel Inhibitors of Cytokine-induced I B Phosphorylation and Endothelial  
593 Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo. *J. Biol.*  
594 *Chem.* **272**, 21096–21103
- 595 35. Douglas, T. A., Brennan, S., Gard, S., Berry, L., Gangell, C., Stick, S. M., Clements, B. S.,  
596 and Sly, P. D. (2009) Acquisition and eradication of *P. aeruginosa* in young children with  
597 cystic fibrosis. *Eur. Respir. J.* **33**, 305–311
- 598 36. Eickmeier, O., Huebner, M., Herrmann, E., Zissler, U., Rosewich, M., Baer, P. C., Buhl, R.,  
599 Schmitt-Grohé, S., Zielen, S., and Schubert, R. (2010) Sputum biomarker profiles in cystic  
600 fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between  
601 pulmonary function. *Cytokine* **50**, 152–157
- 602 37. Tang, A., Sharma, A., Jen, R., Hirschfeld, A. F., Chilvers, M. A., Lavoie, P. M., and  
603 Turvey, S. E. (2012) Inflammasome-Mediated IL-1 $\beta$  Production in Humans with Cystic  
604 Fibrosis. *PLoS ONE* **7**, e37689
- 605 38. Lin, B., Noring, R., Steere, A. C., Klempner, M. S., and Hu, L. T. (2000) Soluble CD14  
606 Levels in the Serum, Synovial Fluid, and Cerebrospinal Fluid of Patients with Various  
607 Stages of Lyme Disease. *J. Infect. Dis.* **181**, 1185–1188
- 608 39. Nockher, W. A., Wick, M., and Pfister, H.-W. (1999) Cerebrospinal fluid levels of soluble  
609 CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during  
610 bacterial infections and viral meningitis. *J. Neuroimmunol.* **101**, 161–169
- 611 40. Marcos, V., Latzin, P., Hector, A., Sonanini, S., Hoffmann, F., Lacher, M., Koller, B.,  
612 Bufler, P., Nicolai, T., Hartl, D., and Griese, M. (2010) Expression, regulation and clinical  
613 significance of soluble and membrane CD14 receptors in pediatric inflammatory lung  
614 diseases. *Respir. Res.* **11**, 32

- 615 41. Egerer, K., Feist, E., Rohr, U., Pruss, A., Burmester, G. R., and Dörner, T. (2000) Increased  
616 serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis  
617 in systemic lupus erythematosus. *Lupus* **9**, 614–621
- 618 42. Le-Barillec, K., Si-Tahar, M., Balloy, V., and Chignard, M. (1999) Proteolysis of monocyte  
619 CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. *J.*  
620 *Clin. Invest.* **103**, 1039–1046
- 621 43. Arai, Y., Mizugishi, K., Nonomura, K., Naitoh, K., Takaori-Kondo, A., and Yamashita, K.  
622 (2015) Phagocytosis by human monocytes is required for the secretion of presepsin. *J.*  
623 *Infect. Chemother.* **21**, 564–569
- 624 44. Ikonen, E. (2001) Roles of lipid rafts in membrane transport. *Curr. Opin. Cell Biol.* **13**,  
625 470–477
- 626 45. Nichols, B. J., Kenworthy, A. K., Polishchuk, R. S., Lodge, R., Roberts, T. H., Hirschberg,  
627 K., Phair, R. D., and Lippincott-Schwartz, J. (2001) Rapid Cycling of Lipid Raft Markers  
628 between the Cell Surface and Golgi Complex. *J. Cell Biol.* **153**, 529–542
- 629 46. Miwako, I., Yamamoto, A., Kitamura, T., Nagayama, K., and Ohashi, M. (2001)  
630 Cholesterol requirement for cation-independent mannose 6-phosphate receptor exit from  
631 multivesicular late endosomes to the Golgi. *J. Cell Sci.* **114**, 1765–1776
- 632 47. Frey, T. and De Maio, A. (2007) Increased Expression of CD14 in Macrophages after  
633 Inhibition of the Cholesterol Biosynthetic Pathway by Lovastatin. *Mol. Med.* **13**, 592–604
- 634 48. Jersmann, H. P. (2005) Time to abandon dogma: CD14 is expressed by non-myeloid lineage  
635 cells. *Immunol. Cell Biol.* **83**, 462–467
- 636 49. Schmitz, G. and Orsó, E. (2002) CD14 signalling in lipid rafts: new ligands and co-  
637 receptors. *Curr. Opin. Lipidol.* **13**, 513–521
- 638 50. Dentener, M. A., Bazil, V., Asmuth, E. J. V., Ceska, M., and Buurman, W. A. (1993)  
639 Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and  
640 IL-8 release by human monocytes and alveolar macrophages. *J. Immunol.* **150**, 2885–2891
- 641 51. Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., and Nuñez, G. (2009) The Inflammasome:  
642 A Caspase-1 Activation Platform Regulating Immune Responses and Disease Pathogenesis.  
643 *Nat. Immunol.* **10**, 241
- 644 52. Yu, H. B. and Finlay, B. B. (2008) The Caspase-1 Inflammasome: A Pilot of Innate Immune  
645 Responses. *Cell Host Microbe* **4**, 198–208

- 646 53. Yu, B., Hailman, E., and Wright, S. D. (1997) Lipopolysaccharide binding protein and  
647 soluble CD14 catalyze exchange of phospholipids. *J. Clin. Invest.* **99**, 315–324  
648  
649

650 **AUTHOR CONTRIBUTIONS**

651  
652 M. Lévêque, K. Simonin-Le Jeune and C. Martin-Chouly designed research; M. Lévêque, K.  
653 Simonin-Le Jeune and C. Martin-Chouly performed the experiments; S; Moulis, C. Belleguic, G.  
654 Brinchault, B. Desrues, S. Le Trionnaire, J-P. Gangneux and S. Jouneau contributed new reagents  
655 or analytic tools; M. Lévêque and C. Martin-Chouly analyzed data; M. Lévêque, M-T.  
656 Dimanche-Boitrel and C. Martin-Chouly wrote the paper.  
657

658 **ACKNOWLEDGEMENTS**

659

660 We would particularly like to thank Mrs. Laurence Hiard and the nurses Mrs. Marie-Thérèse  
661 Jousseume and Mrs. Isabelle Berhault at CRCM (*Centre de Ressources et de Compétences pour*  
662 *la Mucoviscidose*) from Rennes University Hospital. This work is supported by the Cystic  
663 Fibrosis French Foundation “Vaincre La Mucoviscidose” (RF20130500807).

664

665 **FIGURE LEGENDS**

666  
667 **Figure 1. Soluble CD14 level in plasma and CD14 gene expression in macrophages.** (A)  
668 sCD14 levels in plasma from healthy subjects (non-CF,  $n=8$ ) and CF patients ( $n=12$ , patients 1-  
669 12, supplemental Table 1), as measured using an ELISA assay. Each symbol represents a single  
670 individual, and the line is the mean. (B) CD14 gene expression in non-CF macrophages ( $n=14$ )  
671 and CF macrophages ( $n=15$ , patients 6, 13-26; supplemental Table I). mRNA levels were  
672 determined by RT-qPCR (supplemental Table 2). Each symbol represents a single individual, and  
673 the line is the mean. (C) Neosynthesis (O.D.) and total (pg/ml) sCD14 in macrophage supernatant  
674 from healthy subjects (non-CF,  $n=5$ ) and CF patients ( $n=5$ , patients 6, 13-16, supplemental Table  
675 1). The data are shown as the mean  $\pm$  SEM. Mann-Whitney test: \*  $p<0.05$  vs. non-CF  
676 macrophages.

677  
678 **Figure 2. Altered CF macrophage phenotype is associated with markedly decreased**  
679 **expression and activity of proteases.** (A) The inhibition of metalloproteases by EDTA (0.1 mM,  
680 24 hours) did not influenced sCD14 secretion in non-CF macrophages ( $n=8$ ) (B) MMP-9  
681 expression is reduced in CF macrophages ( $n=6$ , patients 6, 13-16 and 32, supplemental Table 1)  
682 vs. non-CF macrophages ( $n=9$ ). Gene expression was determined by RT-qPCR (supplemental  
683 Table 2). (C) In a representative gelatin zymogram, latent MMP-9 (92 kDa) is observed based on  
684 proteolysis areas, which appeared as clear bands against a dark background. After scanning the  
685 gels, both the surface and intensity of the lysis bands were analyzed by densitometry (bar graph)  
686 and showed decreased expression of latent MMP-9 in CF macrophages ( $n=12$ , patients 33-44,  
687 supplemental Table 1) vs. non-CF macrophages ( $n=11$ ). The results were expressed vs. the  
688 relative latent MMP-9 intensity observed in the supernatant of non-CF macrophages. (D, E, F)  
689 The inhibition of cysteine proteases by e64d (D, 1  $\mu$ M, 24 hours,  $n=10$ ), aspartic proteases by  
690 pepstatin A (E, 1  $\mu$ M, 24 hours,  $n=4$ ) and serine proteases by aprotinin (0.3  $\mu$ g/ml, 24 hours,  $n=9$ )  
691 did not influenced sCD14 secretion in non-CF macrophages. The data are shown as the mean  $\pm$   
692 SEM. Mann-Whitney test: \*  $p<0.05$  and \*\*  $p<0.01$  vs. non-CF macrophages.

693  
694 **Figure 3. PI-PLC increases sCD14 production in non-CF macrophages.** sCD14 levels were  
695 measured in supernatants from macrophages using an ELISA assay. (A) PI-PLC (1 U/ml, 2

696 hours) significantly increases sCD14 production by non-CF macrophages ( $n=11$ ). The inhibition  
697 of PI-PLC by U-73122 (12.5  $\mu\text{M}$ , 1 hour pretreatment) inhibited PI-PLC-induced sCD14  
698 secretion in non-CF macrophages ( $n=7$ ). (B) U-73122 (12.5  $\mu\text{M}$ , 24 hours) did not prevent  
699 spontaneous sCD14 production by CF macrophages ( $n=6$ , patients 43, 45-49; supplemental Table  
700 1). The data are shown as the mean  $\pm$  SEM. Ratio Student's t-test: ##  $p<0.01$  vs. untreated non-  
701 CF macrophages; \*\*  $p<0.01$  vs. PI-PLC-treated non-CF macrophages.

702  
703 **Figure 4. Impact of intracellular protein transport on sCD14 production by non-CF and CF**  
704 **macrophages.** (A) Free cholesterol level is increased in CF ( $n=8$ , patients 43, 47, 50-55;  
705 supplemental Table 1) vs non-CF ( $n=4$ ) macrophages (B) Water-soluble cholesterol (15  $\mu\text{g/ml}$ ; 24  
706 hours) significantly increases sCD14 production by non-CF macrophages ( $n=5$ ). (C) Brefeldin A  
707 (Bref A; 100 ng/ml; 3 h) significantly decreased sCD14 production by non-CF ( $n=5$ ) and CF  
708 ( $n=5$ , patients 56-60; supplemental Table 1) macrophages. Levels in the supernatants were  
709 measured using an ELISA assay. The data are shown as the mean  $\pm$  SEM. Mann-Whitney test: \*\*  
710  $p<0.01$  vs. non-CF macrophages. Ratio Student's t-test: #  $p<0.05$  vs. untreated non-CF  
711 macrophages and §  $p<0.05$  vs. untreated CF macrophages.

712  
713  
714 **Figure 5. Human recombinant sCD14 induces the expression and secretion of pro-**  
715 **inflammatory cytokines in non-CF macrophages.** (A) IL-1 $\beta$ , IL-8 and TNF- $\alpha$  mRNA  
716 expression was quantified by RT-qPCR in non-CF macrophages treated with hr-sCD14 (100 and  
717 500 ng/ml, 6 hours and 24 hours). The data are shown as the mean  $\pm$  SEM of four and five  
718 independent experiments for 6 hours and 24 hours, respectively. (B) IL-1 $\beta$ , IL-8 and TNF- $\alpha$   
719 release were measured by using an ELISA assay in supernatants from non-CF macrophages  
720 treated with hr-sCD14 (1 to 500 ng/ml, 24 hours). The data are shown as the mean  $\pm$  SEM ( $n=6-$   
721 11,  $n=4$  and  $n=3-6$  for IL-1 $\beta$ , IL-8 and TNF- $\alpha$ , respectively). Ratio Student's t-test: \*  $p<0.05$ ; \*\*  
722  $p<0.01$ ; \*\*\*  $p<0.001$  and \*\*\*\*  $p<0.0001$  vs. untreated macrophages.

723  
724 **Figure 6. NF- $\kappa\text{B}$  pathway is involved in the sCD14-induced production of pro-inflammatory**  
725 **cytokines in non-CF macrophages.** (A) Cytosol P-I $\kappa\text{B}\alpha$  and I $\kappa\text{B}\alpha$  expression were determined

726 by Western blotting of the total protein fraction from non-CF macrophages treated with hr-sCD14  
727 (500 ng/ml, 0 to 60 min, representative blot of three independent experiments). Equal protein  
728 loading was controlled via HSC-70 detection. (B) NFκB p65 activation was measured using an  
729 assay in non-CF macrophages that were treated or not treated with hr-sCD14 ( $n=5$ ; 500 ng/ml, 24  
730 hours). A positive control was used to establish the result. (C) IL-1β, IL-8 and TNF-α gene  
731 expression was analyzed by RT-qPCR in non-CF macrophages treated or not treated with hr-  
732 sCD14 (500 ng/ml, 6 hours) in the absence and presence of an NF-κB inhibitor (Bay 11-7082, 10  
733 μM, 1 hour pretreatment,  $n=5$ ) (D) IL-1β, IL-8 and TNF-α protein expression were quantified  
734 using an ELISA assay in non-CF macrophages that were treated or not treated with hr-sCD14  
735 (500 ng/ml, 24 hours) in the absence or presence of Bay 11-7082 (1 and 10 μM, 1 hour  
736 pretreatment;  $n=4$ ,  $n=4$  and  $n=5$  for IL-1β, IL-8 and TNF-α, respectively). The data are shown as  
737 the mean ± SEM. Ratio Student's t-test: \*  $p<0.05$  and \*\*\*  $p<0.001$  vs. untreated macrophages; #  
738  $p<0.05$  and ##  $p<0.01$  vs. hr-sCD14-treated macrophages.

739  
740 **Figure 7. Caspase-1 is involved in the sCD14-induced production of IL-1β in non-CF**  
741 **macrophages.** (A) Pro-caspase 1 and caspase 1 expression were determined by Western blotting  
742 analysis of the total protein fraction from non-CF macrophages treated with hr-sCD14 (500  
743 ng/ml, 0 to 60 min, a representative blot of three independent experiments). (B) IL-1β secretion  
744 was measured using an ELISA assay in supernatants from non-CF macrophages treated with hr-  
745 sCD14 (500 ng/ml, 0 to 1440 min). The data are shown as the mean ± SEM ( $n=7$ ). (C) IL-1β  
746 secretion was measured using an ELISA assay in supernatants from non-CF macrophages treated  
747 or not treated with hr-sCD14 (500 ng/ml, 24 hours) in the absence or presence of the caspase 1  
748 inhibitor Z-WEHD-FMK (1 to 30 μM, 1-hour pretreatment). The data are shown as the mean ±  
749 SEM ( $n=4$ ). Ratio Student's t-test: \*  $p<0.05$  and \*\*  $p<0.01$  vs. untreated macrophages; #  $p<0.05$   
750 vs. hr-sCD14-treated macrophages.

751  
752 **Figure 8. NLRC4 and NLRP3 inflammasome pathways are involved in IL-1β secretion in**  
753 **non-CF macrophages treated with hr-sCD14.** (A and B) The efficiency of transfection with  
754 NLRC4 siRNA or NLRP3 siRNA was assessed by Western blotting of the total protein fraction  
755 from non-CF macrophages. The bar graph shows the results of densitometric analysis ( $n=6$ ). The




756 results were expressed vs. the relative intensity observed in Control siRNA-treated non-CF  
757 macrophages. (C) IL-1 $\beta$  release was measured by ELISA in supernatants from non-CF  
758 transfected macrophages that were treated or not treated with hr-sCD14 (500 ng/ml, 24 hours;  
759  $n=6$ ). The data are shown as the mean  $\pm$  SEM. Ratio Student's t-test: \*\*  $p<0.01$  vs. siControl-  
760 treated macrophages; ##  $p<0.01$  vs. untreated macrophages; §  $p<0.05$  and §§  $p<0.01$  vs. hr-  
761 sCD14-treated macrophages.

762  
763 **Figure 9. sCD14-induced cytokine release by non-CF macrophages is reversed by**  
764 **antagonists that target CD14 or TLR-4.** IL-1 $\beta$ , IL-8 and TNF- $\alpha$  secretion was measured by  
765 ELISA in supernatants from non-CF macrophages that were treated or not treated with hr-sCD14  
766 (500 ng/ml, 24 hours) in the absence or presence of an anti-CD14 neutralizing antibody (CD14-  
767 ab, 10  $\mu$ g/ml, 1-hour pretreatment), a TLR-4 antagonist (LPS-RS, 2  $\mu$ g/ml, 1-hour pretreatment),  
768 an anti-TLR4 neutralizing antibody (TLR4-ab, 10  $\mu$ g/ml, 1-hour pretreatment) or the IgG2a  
769 control (10  $\mu$ g/ml, 1 hour pretreatment). The data are shown as the mean  $\pm$  SEM ( $n=3-6$ ,  $n=3-6$   
770 and  $n=3-6$  for IL-1 $\beta$ , IL-8 and TNF- $\alpha$ , respectively). Ratio Student's t-test: \*  $p<0.05$  and \*\*  
771  $p<0.01$  vs. hr-sCD14-treated macrophages.


# Figure 1

Fig 1




# Figure 2

Fig 2




# Figure 3

Fig 3




# Figure 4

Fig 4




# Figure 5

Fig 5




# Figure 6

Fig 6



# Figure 7


Fig 7






# Figure 8

Fig 8



# Figure 9

Fig 9




**Table S1:** Characteristics of CF patients

Patient	Age	Sex	Genotype	Microbiology	BMI	FEV1 % predicted
1	32	F	F508del / F508del	P.a / A.f / S.a	15	45
2	33	M	F508del / F508del	P.a / A.f / S.a	22,9	66
3	34	F	F508del / W486X	P.a / S.a	19,6	37
4	22	F	F508del / F508del	P.a / A.f / S.a	16,8	32
5	39	M	F508del / G551D	Af	22,1	40
6	32	M	F508del / F508del	P.a / S.a	20,1	82
7	20	M	F508del / F508del	P.a / A.f / S.a	19,9	66
8	20	M	F508del / F508del	S.a	23,2	98
9	39	F	F508del / 2789+5G→A	P.a / S.a	19,3	66
10	22	M	F508del / F508del	A.f / S.a	19,5	78
11	22	F	1248+1G→A	S.a	22,7	104
12	20	F	F508del / I507del	P.a / A.f	18,4	61
13	30	F	F508del / 1248+1G→A	P.a / S.a	18,3	33
14	31	F	F508del / N1303K	P.a / A.f / S.a	15,4	28
15	22	F	F508del / F508del	P.a / A.f / S.a	19,6	79
16	34	M	F508del / F508del	P.a / A.f / S.a	20,5	51
17	27	F	F508del / F508del	A.f / S.a	20,5	97,2
18	35	F	F508del / F508del	P.a / S.a	19,1	30,2
19	43	M	F508del / G551D	P.a	20,9	79,1
20	28	F	1248+1G→A	A.f / S.a	20,7	90,5
21	40	M	F508del / F508del	P.a / A.f	21,9	48,7
22	18	F	F508del / F508del	None	24,1	100,4
23	37	F	R600S / CFTRdup4-10	S.a	18,6	95
24	20	F	F508del / S945L	A.f / S.a	21,3	68,4
25	25	M	F508del / F508del	A.f / S.a	24,4	58,5
26	24	F	F508del / F508del	P.a / A.f / S.a	16,5	28,4
27	19	M	F508del / 2789+5G→A	S.a	22,23	94,7
28	40	F	F508del / S492F	P.a / S.a	27,82	55,3
29	53	F	F508del / 2789+5G→A	P.a / A.f	17,61	36
30	28	M	F508del / F508del	A.f	23,74	103
31	53	M	F508del / 2789+5G→A	S.a	22,14	96,2
32	20	M	F508del / F508del	A.f / S.a	22,3	62
33	19	M	F508del / F508del	P.a / A.f	20,4	91
34	26	M	F508del / F508del	S.a	20,2	58,7
35	37	M	F508del / F508del	S.a	21,1	77,4
36	23	F	F508del / F508del	S.a	17,1	54,5
37	49	F	F508del / 3272-26A→G	P.a / S.a	22,8	62,2
38	31	F	F508del / G91R	P.a / S.a	24,3	61,5
39	19	F	F508del / F508del	S.a	18,8	96
40	27	M	F508del / F508del	S.a	20,2	73,1
41	26	F	F508del / F508del	P.a / A.f / S.a	19,1	67
42	33	M	F508del / F508del	P.a	22,2	64,4
43	18	F	F508del / F508del	None	25,8	102,1
44	37	F	F508del / F508del	S.a	19,1	77,5
45	21	F	F508del / G551D	S.a	22,5	103,7
46	46	M	F508del / 2789+5G→A	A.f / S.a	22,2	96,6
47	35	F	F508del / F508del	P.a / S.a	19,3	35,2
48	25	M	F508del / F508del	A.f / S.a	23,5	55,3
49	39	M	F508del / F508del	P.a	21	49
50	18	F	F508del / F508del	P.a / A.f / S.a	19,1	62,3
51	23	M	F311L / N1303K	S.a	18,5	93,8
52	21	F	F508del / F508del	P.a / A.f / S.a	18,4	86,7
53	26	M	F508del / S1251N	P.a / S.a	18,81	41,1
54	23	F	F508del / F508del	P.a / S.a	16,86	33,7
55	38	F	F508del / F508del	None	18,2	41
56	30	M	F508del / 1749insTA	P.a / A.f / S.a	18,3	21,1
57	32	F	F508del / 4382delA	P.a / A.f / S.a	18	29,5
58	23	F	F508del / 1677delTA	P.a / A.f	18	49
59	52	M	F508del / 2789+5G→A	Af	22,5	107,9
60	38	M	F508del / 1078delT	P.a / A.f / S.a	21,7	63


**Abbreviations :** A.f.: *Aspergillus fumigatus*; P.a.: *Pseudomonas aeruginosa*; S.a.: *Staphylococcus aureus*  
**FEV1:** Force Expiratory Volume in one second

**Table S2:** List of primer sequences used for RT-qPCR analysis in this study

Target genes	Primer	Sequence (5' to 3')
<b>18S</b>	Hs_RRN18S_1_SG	QT00199367
<b>18S</b>	Forward	CGCCGCTAGAGGTGAAATTC
	Reverse	TTGGCAAATGCTTTTCGCTC
<b>CD14</b>	Hs_CD14_1_SG	QT00208817
<b>IL-1<math>\beta</math></b>	Hs_IL1B_1_SG	QT00021385
<b>IL-8</b>	Hs_CXCL8_1_SG	QT00000322
<b>TNF<math>\alpha</math></b>	Forward	AACCTCCTCTCTGCCATC
	Reverse	ATGTTTCGTCCTCCTCACA
<b>MMP-9</b>	Forward	TCTTCCCTGGAGACCTGAGA
	Reverse	ATTTGACTCTCCACGCATC
<b>MMP-12</b>	Forward	ACACATTTGCCTCTCTGCT
	Reverse	ATTGTCAGGATTTGGCAAGC
<b>Cathepsin B</b>	Forward	AGAATGGCACACCCTACTGG
	Reverse	GCCACCACTTCTGATTCGAT
<b>Cathepsin D</b>	Forward	GTACATGATCCCCTGTGAGAAGGT
	Reverse	GGGACAGCTTGTAGCCTTTGC
<b>Cathepsin F</b>	Forward	GCCTGTCCGTCTTTGTCAAT
	Reverse	TGGCTTGCTTCATCTTGTTG
<b>Cathepsin K</b>	Forward	CCGCAGTAATGACACCCTTT
	Reverse	GCACCCACAGAGCTAAAAGC
<b>Cathepsin S</b>	Forward	TGGGAGACATGACCAGTGAA
	Reverse	AGCAAGCACCACAAGAACCT
<b>Adam 9</b>	Forward	TGCAAATGTCTTCAGGGAAC
	Reverse	TGCATTAACCTCACCGATGAC
<b>Adam 10</b>	Forward	CATTGCTGAATGGATTGTGG
	Reverse	GAGCCTGGAAGTGGTTTACG
<b>Adam 12</b>	Forward	AACCTCGCTGCAAAGAATGTG
	Reverse	CTCTGAAACTCTCGGTTGTCTG
<b>Adam 17</b>	Forward	ACCTGAAGAGCTTGTTTCATCGAG
	Reverse	CCATGAAGTGTTCCGATAGATGTC
<b>PLC<math>\gamma</math></b>	Forward	AACCAGAAGTCCTTTGTCTTCATC
	Reverse	CTGGTTCTTCTCCCAGTACTTCAT



**FIGURE S1. Proteases and phospholipase C- $\gamma$  gene expressions in non-CF and CF macrophages.** (A) MMP-12 ( $n=4$ , patients 6, 13, 15-16; supplemental Table 1), (B to E) Adam 9, Adam 10, Adam 12 ( $n=6$ , patients 17-18, 20-22, 24; supplemental Table 1) and Adam 17 ( $n=6$ , patients 17, 21-22, 24, 26, 41; supplemental Table 1), (F to J) cathepsin-B, cathepsin-D, cathepsin-F, cathepsin-K and cathepsin-S ( $n=3-6$ , patients 15-16, 32; supplemental Table 1) and (K) phospholipase C- $\gamma$  (PLC $\gamma$ ,  $n=5-6$ , patients 17, 18, 20, 22, 24; supplemental Table 1). Gene (mRNA) expression was quantified in CF and non-CF macrophages by RT-qPCR. The data are shown as the mean  $\pm$  SEM. Mann-Whitney test: \*  $p < 0.05$  vs. non-CF macrophages.



**FIGURE S2. sCD14 potentiates LPS-induced inflammatory cytokines/chemokines production in non-CF macrophages.** IL-1 $\beta$ , IL-8 and TNF- $\alpha$  levels were measured using an ELISA assay in non-CF macrophages incubated with LPS (from *P. aeruginosa*, 100 ng/ml) in the absence and presence of sCD14 (500 ng/ml) ( $n=8$ ). Ratio Student's t-test: \*  $p < 0.05$ ; \*\*  $p < 0.01$  and \*\*\*\*  $p < 0.0001$  vs LPS-treated macrophages.